2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
Description of Macitentan: Macitentan is an investigational drug being studied For the treatment of pulmonary arterial hypertension. It acts as a dual endothelin receptor antagonist and is being developed by Actelion. A Phase III clinical trial was successfully completed in 2012.
For the detailed information about the solubility of macitentan (Actelion-1, ACT-064992) in water, the solubility of macitentan (Actelion-1, ACT-064992) in DMSO, the solubility of macitentan (Actelion-1, ACT-064992) in PBS buffer, the animal experiment（test） of macitentan (Actelion-1, ACT-064992),the in vivo,in vitro and clinical trial test of macitentan (Actelion-1, ACT-064992),the cell experiment（test） of macitentan (Actelion-1, ACT-064992),the IC50, EC50 and Affinity of macitentan (Actelion-1, ACT-064992), please contact DC Chemicals.
